'Evidence 360' will be a new data source for real-world medical data from IMS Health
Collaboration with Remedy Informatics will combine observational data with electronic health records and claims
“Real world evidence” is the term that some in the medical and life sciences arena are using to describe data with the quality of a clinical trial, but the results of actual patients taking medicine or receiving treatment—and with the cost of that healthcare as a cross-reference. IMS Health (Plymouth Meeting, PA) has been a player in this kind of data-gathering for years, through its longitudinal studies, prescription sales data and other resources; now it is taking that type of data gathering a step further with a strategic alliance with Remedy Informatics (Salt Lake City, UT). That company has developed a technology platform, Mosaic, to enable researchers to combine datasets from different databases into meaningful compilations; the company has been working for many years in clinical research, patient registries and related information services.
“’Real world evidence’ is not new to us, but the growing capabilities of data from sources like electronic health records enables a broader and more meaningful analysis of healthcare trends,” says Jon Resnick, VP and GM of the Real World Evidence Solutions group at IMS Health. The combined offering, IMS Evidence 360°, will “enable pharmaceutical and medical device manufacturers, payers and providers to link and analyze complex healthcare data sets,” and be “a key component of IMS Health’s expanded RWE platform supporting a broad range of applications, from epidemiological studies and comparative effectiveness and safety research, to commercial analytics,” according to IMS.
Resnick notes that in the broad spectrum of healthcare data from clinical trials to observational studies to claims data, pharma and other life sciences companies have had a tough time getting an accurate picture of the ultimate customer: the patient. Evidence 360° is expected to be a solution that will provide pharma companies with the outcomes results that they increasingly need to deliver to payers as justification for the products they sell.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.
Reimagining Closed-Loop Marketing Strategies for Pharma Companies
November 21st 2024The pharmaceutical industry is evolving, and so are the strategies needed to connect with healthcare professionals. Closed-loop marketing (CLM) has become essential in delivering personalized, data-driven engagement that resonates with physicians and improves key outcomes, such as enhancing patient care, increasing
Maximize Pharma’s Potential with AI-Ready Data for Commercial Excellence
November 21st 2024As the pharmaceutical industry embraces the power of AI, having data that’s large, diverse, and well-structured is critical for driving innovation and improving outcomes. Ensuring your data is AI-ready and can be used with more advanced solutions enables your teams to make informed strategic decisions, predict trends, enhance customer engagements and drive overall strategy.
